Header cover image

Japanese (NIKKEI) Life Sciences Industry Analysis

UpdatedJan 26, 2022
DataAggregated Company Financials
  • 7D-3.7%
  • 3M-27.0%
  • 1Y-7.7%
  • YTD-17.6%

Over the last 7 days, the Life Sciences industry has dropped 3.0%, driven by a pullback from CellSource of 8.2%. As for the longer term, the industry's performance has been flat for the past year.

Industry Valuation and Performance

Has the Japanese Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Thu, 27 Jan 2022JP¥232.4bJP¥136.0bJP¥6.8b19.5x
Sat, 25 Dec 2021JP¥286.6bJP¥136.0bJP¥6.8b23.5x
Mon, 22 Nov 2021JP¥349.8bJP¥135.7bJP¥6.9b28.1x
Wed, 20 Oct 2021JP¥375.1bJP¥198.7bJP¥8.1b25.9x
Fri, 17 Sep 2021JP¥378.1bJP¥198.4bJP¥7.9b25.6x
Sun, 15 Aug 2021JP¥355.8bJP¥201.8bJP¥5.0b25.9x
Thu, 10 Jun 2021JP¥321.0bJP¥194.0bJP¥2.5b29.5x
Wed, 03 Mar 2021JP¥287.0bJP¥191.7bJP¥152.2m30.2x
Sat, 05 Dec 2020JP¥284.8bJP¥190.0b-JP¥434,535,000.0047.9x
Tue, 08 Sep 2020JP¥307.2bJP¥189.8bJP¥2.0b18.3x
Mon, 01 Jun 2020JP¥296.6bJP¥193.4bJP¥2.7b22.1x
Thu, 05 Mar 2020JP¥207.1bJP¥190.2bJP¥1.9b20x
Sun, 08 Dec 2019JP¥256.0bJP¥187.0bJP¥2.1b37.6x
Sat, 31 Aug 2019JP¥213.0bJP¥184.1bJP¥1.5b30.5x
Tue, 04 Jun 2019JP¥234.6bJP¥181.6bJP¥1.3b17.8x
Fri, 08 Mar 2019JP¥258.3bJP¥180.0b-JP¥879,502,000.0021.9x
PE Ratio


Total Market Cap: JP¥230.6bTotal Earnings: -JP¥879,502,000.00Total Revenue: JP¥180.0b0%0%0%3 Year10 Year

Current Industry PE: Investors are more pessimistic on the industry, considering it's trading at a PE ratio of 19.5x which is lower than its 3-year average PE of 27.1x. It appears they believe that earnings will not grow as fast as they have historically.

Past Earnings Growth: Total earnings for the Life Sciences industry have gone up over the last three years, and the industry is now profitable. However revenues have declined 8.9% per year. This means that less sales are being generated overall, but since the cost of doing business is lower, profits have been increasing.

Industry Trends

Which industries have driven the changes within the Japanese Life Sciences industry?

Clinical Research and Equipment-3.71%

Industry PE: Investors are most optimistic about the Clinical Research and Equipment industry even though it's trading below its 3-year average PE ratio of 27.1x. However analysts are expecting annual earnings growth of 32%, which is lower than the prior year's growth of 187% per year. So the market might believe that analysts are underestimating future growth.

Forecasted Growth: Analysts are most optimistic on the Clinical Research and Equipment industry, expecting annual earnings growth of 32% over the next 5 years. However this is lower than its past earnings growth rate of 187% per year.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
2309 CMIC HOLDINGSJP¥1.46k2.9%
4583 Chiome BioscienceJP¥174.005.5%
6090 Human Metabolome TechnologiesJP¥581.000.3%
6190 PhoenixBioJP¥503.000.6%
4570 Immuno-Biological LaboratoriesJP¥343.000.3%
Simply Wall St
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News